ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) faces challenges with ineffective drug delivery and poor patient prognosis.
• Tumor suppressor microRNA-34a (miR-34a) is downregulated in PDAC, while Polo-like kinase 1 (PLK1) is highly expressed, correlating with poor survival.

Purpose of the Study:

• To develop a novel drug delivery system for co-delivering miR-34a mimic and PLK1 inhibitor volasertib for PDAC treatment.
• To evaluate the efficacy and safety of this combination therapy in preclinical models.

Main Methods:

• A polymer, poly(ethylene glycol)-poly[aspartamidoethyl( p-boronobenzyl)diethylammonium bromide] (PEG-B-PAEBEA), was synthesized to form micelles encapsulating volasertib and complexing with miR-34a.
• The combination therapy's antiproliferative activity, cell cycle effects, and in vivo efficacy were assessed in pancreatic cancer models.
• Systemic toxicity was evaluated through histological examination of major organs.

Main Results:

• PEG-B-PAEBEA micelles achieved efficient co-delivery of volasertib and miR-34a.
• Combination treatment exhibited synergistic effects, superior antiproliferative activity, enhanced G2/M phase arrest, and suppressed colony formation, leading to cancer cell death.
• In vivo studies showed significant tumor volume reduction with negligible systemic toxicity.

Conclusions:

• PEG-B-PAEBEA micelles represent a promising nanocarrier for the co-delivery of volasertib and miR-34a mimic.
• This combination therapy holds potential for effective treatment of pancreatic cancer with reduced systemic side effects.